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ABSTRACT
Adult T-cell lymphoblastic lymphoma is a relatively rare aggressive type of non-Hodgkin lymphoma with
frequent involvement of extranodal sites. Because of the rarity of this malignancy, it is treated variably and
often suboptimally, using approaches similar to those used for other types of aggressive non-Hodgkin
lymphomas, with the consequence that outcome is often suboptimal. The collective experience in the man-
agement of adult T-cell lymphoblastic lymphoma suggests a good outcome for patients with no adverse
prognostic factors who are treated with an acute lymphocytic leukemia–like treatment strategy. Patients with
adverse prognostic features should be considered for more aggressive therapy—specifically, high-dose che-
motherapy and hematopoietic stem cell transplantation. This article will attempt to review the current status
of chemotherapy treatment programs and the relative merits of the different hematopoietic stem cell trans-
plantation programs in this disease, particularly in relation to the pathologic and clinical features that correlate
with disease prognosis.
© 2005 American Society for Blood and Marrow Transplantation
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lNTRODUCTION
Precursor T-cell lymphoblastic lymphoma (T-LBL)
ccounts for most cases of childhood T-cell lineage
on-Hodgkin lymphomas (NHL) [1] but is relatively
are in adults; it accounts for 2% of all NHL (1.7%
or T-LBL and 1% for B-cell lymphoblastic lym-
homa [B-LBL]) [2,3]. Approximately 80% of adult
ases of lymphoblastic lymphoma (LBL), which is
ore commonly seen in adolescent and young adult
ales, have a T-cell phenotype. T-LBL is a clinically
ggressive disease with frequent involvement of ex-
ranodal sites, particularly the bone marrow (BM) and
entral nervous system (CNS) [4-6]. Several issues
elated to the management of this disease remain
ontroversial. In this article, we attempt to summarize
he relatively limited clinical studies about the treat-
ent of this rare disease. c
B&MTATHOLOGIC FEATURES
orphology
The historic milestones in the evolution of the
erm lymphoblastic lymphoma in the literature go back
o 1916, when Sternberg [7] described the ﬁrst case of
leukosarkoma,” which had clinical features of what
oday is known as LBL. In 1932, Cooke [8] described
male patients with mediastinal masses. In the orig-
nal Rappaport classiﬁcation of lymphomas, LBL was
ncluded among the diffuse poorly differentiated lym-
hocytic lymphomas [9]. In 1973, Smith et al. [10]
tudied the immunologic characteristics of a case and
etermined that “Sternberg sarcoma” originated from
hymic lymphocytes. In 1975, Barcos and Lukes [11]
nd Lukes and Collins [12] used the term convoluted
ymphocytic lymphoma because of the characteristic nu-
lear convolutions seen in most cases. In the following
739
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7ear, Nathwani et al. [13] used the term lymphoblastic
ymphoma because of the similarities between LBL
lasts and acute lymphocytic leukemia (ALL) blasts.
BL was classiﬁed as International Working Formu-
ation category I [14,15] and as a convoluted type of
BL according to the Kiel classiﬁcation, which was
ased on immunophenotypic and cytologic character-
stics [16,17]. In the Revised European-American
ymphoma classiﬁcation [18,19] and more recently in
he World Health Organization classiﬁcation of lym-
hoid malignancies [20], LBL is classiﬁed under
-cell neoplasms (precursor T-LBL; International
lassiﬁcation of Diseases-Oncology code 9729/3) and
recursor B-cell neoplasms (precursor B-LBL; Inter-
ational Classiﬁcation of Diseases-Oncology code
728/3).
Precursor T-LBL, a neoplasm of lymphoblasts
ommitted to the T-cell lineage, is typically composed
f small to medium-sized blast cells with scant cyto-
lasm, moderately condensed to dispersed chromatin,
nd inconspicuous nucleoli. The lymph node gener-
lly shows complete effacement, with involvement of
he capsule. A “starry-sky” effect may be present.
artial involvement in a paracortical location with
paring of germinal centers may occur. In some cases,
he predominant population of blasts has convoluted
uclei; mitotic ﬁgures may be numerous, and cyto-
lasmic vacuoles may be present in others [5,21]. Be-
ause of the apparent biologic unity of precursor
-lymphoblastic leukemia and T-LBL, the use of one
r the other term in some patients is arbitrary. When
he process is conﬁned to a mass lesion with no or
inimal evidence of blood and marrow involvement,
he diagnosis is lymphoma. With extensive marrow
nd blood involvement, acute lymphoblastic leukemia
s the appropriate term. If the patient presents with a
ass lesion and 25% lymphoblasts in the marrow,
he designation lymphoma is preferred. This is an ar-
itrary distinction, and exceptions may apply [21].
Precursor B-LBL is uncommon, accounting for
10% of cases of LBL. Unlike precursor T-LBL,
-LBL usually involves extranodal sites, most often
he skin; rarely presents as a mediastinal mass; has a
etter prognosis, with a good response to aggressive
hemotherapy; and rarely progresses to precursor
-cell ALL. The neoplastic cells of B-LBL are mor-
hologically indistinguishable from those of B-cell
LL and are typically of small to medium size, with
ne chromatin, inconspicuous nucleoli, and a high
itotic rate [22,23].
mmunophenotype
In general, precursor T- and B-cell neoplasms are
elated to the stage of development. However, expres-
ion of numerous asynchronous and aberrant antigens
as been described, and most cases do not ﬁt currently
40ecognized patterns of antigen expression of normal B
nd T precursors. The lymphoblasts in T-LBL ex-
ress variable combinations of T cell–associated anti-
ens, as well as several lineage-nonspeciﬁc antigens
uch as CD45, CD34, and terminal deoxynucleotidyl
ransferase (TdT; Table 1).
The nuclei of LBL blasts stain brightly for TdT
24]. This expression may be useful in follow-up of
inimal residual disease (MRD). Most T-LBL cases
an be correlated with common (57% of the cases),
ature (28%), and immature (15%) thymic immuno-
henotypes, whereas the remaining one third have a
eterogeneous immunophenotype [25-29]. The com-
on and mature phenotypes are characterized by ex-
ression of CD7, CD2, CD5, and cytoplasmic or
urface CD3 antigens [29]. Many cases express CD1a
ith CD4 and/or CD8. Sixty percent of T-LBL cases
oexpress CD3 with the -chain of the T-cell receptor
TCR) [30-33]. T-LBL may also express CD34 (ap-
roximately 75%), HLA-DR (43%), and CD10 (15%-
0% of cases) [34], but they rarely express CD25 [29].
ccasionally, natural killer cell markers such as CD57
r CD16 are coexpressed where a more aggressive
linical course with this form of LBL has been ob-
erved, especially in nonwhite females [35,36]. The
egree of immunophenotypic differentiation seems to
orrelate with TCR chain rearrangement; the imma-
ure phenotypes are most often associated with rear-
anged - or -chain genes [37-39], and rearrange-
ents of the - and -chains are more common in the
ature phenotypes. In adult patients, peripheral
-cell lymphoproliferative disorders should be con-
idered in the differential diagnosis of mature T-LBL.
hese disorders are conspicuously negative for TdT
nd CD1a.
Precursor B-LBL cases typically express TdT,
able 1. Immunophenotypic Proﬁles of Precursor T-Cell Neoplasms
recursor T-cell acute
lymphoblastic
leukemia/lymphoma*
Early T Precursor
CD7, TdT, CD34, wCD45
Immature thymocyte
CD7, TdT,† variable CD34, CD5,
CD38, CD2, cCD3, variable HLA-
DR, wCD45
Common thymocyte
CD7, variable TdT, CD5, CD38,
CD2, CDIa, CD3, variable CD4,
variable CD8, variable HLA-DR,
wCD45
Mature thymocytes
CD7, CD5, variable CD38, CD2,
CD3, CD4 or CD8, CD45
CD indicates cytoplasmic CD; TdT, terminal deoxynucleotidyl
transferase; w, weak.
Occasionally, T-LBL cases coexpress natural killer cell markers
such as CD56 or CD16.
Very rare cases of T-ALL that lack TdT expression have been
described.
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Chemotherapy and Hematopoietic SCT for T-LBL
BLA-DR, CD10, CD19, CD99 (MIC2), CD43,
AX5, and sometimes CD20 and or CD79a antigens.
ecause some cases may be CD20 negative and CD43
ositive, they may be mistaken for T-lineage LBL;
owever, such cases are negative for CD3 and CD5
22].
ytogenetic and Molecular Abnormalities
The most common chromosomal abnormalities in
-LBL involve 14q11-13, including inv(l4)(qll;q32),
nd deletions or translocations involving chromo-
omes 9, 10, and 11, corresponding to sites of TCR
-, -, and -subunit genes found in 47% of T-LBL
29]. Translocation (9;17)(q34;q23) signiﬁes a poor
rognosis with a rapidly progressive disease course
40].
Rare cases of T-LBL, eosinophilia, and myeloid
yperplasia have been observed [41], and in a few cases
here has been an associated t(8; 13)(p11;q11) cytoge-
etic abnormality [42]. Morphology usually reveals
dditional inﬁltration by eosinophils. Subsequent de-
elopment of myeloid malignancies, including acute
yeloid leukemia, myelodysplastic syndrome, and ex-
ramedullary myeloid tumors, has been reported in
hese cases. The unusual myeloproliferative syndrome
ssociated with the translocations t(8; 13)(p11; q12),
(8; 9)(p11; q32), or t(6; 8)(q27; p11) is now collec-
ively known as the 8p11 myeloproliferative disorder
42-44]. The natural history of the 8p11 myeloprolif-
rative syndrome has similarities to chronic myeloid
eukemia (CML), with a chronic phase that ultimately
ransforms into an acute leukemia. Where reported,
he same clonal karyotypic abnormality is seen in both
he lymphoma and myeloid cells; this suggests a com-
on lymphoid/myeloid stem cell as the target for the
riginal transforming event. It is interesting to note
hat fusion of a novel zincﬁnger gene (ZNF198) at
3q12 to the ﬁbroblast growth factor receptor 1 at
p11 leads to constitutive activation of the ﬁbroblast
rowth factor receptor 1 tyrosine kinase in a manner
nalogous to the activation of ABL by BCR in CML
45,46]. More recent ﬁndings suggest a critical role of
TAT5 activation in transformation mediated by the fu-
ion of ZNF198/ﬁbroblast growth factor receptor 1 [47].
are cases of de novo T-LBL with t(11;19)(q:23;p13)
nd MLL gene rearrangement related to antecedent
pipodophyllotoxin exposure for treatment of prior
alignancies have been described [48].
EFINITION OF HIGH-RISK DISEASE AND REPORTED
OOR-PROGNOSTIC FACTORS
A variety of clinical features have been associated
ith a poor prognosis in adult LBL, including features
hat reﬂect the growth and invasive potential of the
umor (advanced stage, hyperleukocytosis, high serum h
B&MTactate dehydrogenase [LDH] level, and involvement
f the CNS, BM, or mediastinum), the patient’s re-
ponse to the tumor (performance status and “B”
ymptoms), the patient’s ability to tolerate therapy
older age and performance status), and the chemo-
ensitivity of the tumor (ability and time to achieve
omplete remission [CR] and type of chemotherapy).
o chromosomal or molecular abnormalities have
een consistently shown to carry prognostic signiﬁ-
ance except for the t(9;17)(q34;q3) karyotype, which
as been associated with an aggressive clinical course
n children [40]. Attempts have been made to divide
BL patients into 2 prognostic groups: good risk and
oor risk. The latter includes patients with various
rognostic features for poor risk, as shown in Table 2.
Deﬁning a “poor risk” category of patients is im-
ortant, because they are potential candidates for
ore intensive therapy and stem cell transplantation
SCT) after the achievement of CR, to improve dis-
ase-free survival (DFS) and, consequently, overall
urvival. Several attempts have been made to combine
isk factors in prognostic indices. However, a convinc-
ng prognostic model has not yet been deﬁned for
dult LBL [3].
Coleman et al. [49] devised a risk stratiﬁcation
ystem based on the presence or absence of marrow or
NS disease, Ann Arbor stage IV, and the serum
DH level. Good-risk patients with LBL (deﬁned as
nn Arbor stage I to III or stage IV with no marrow
r CNS involvement and LDH less than 1.5 times
ormal) had a 5-year relapse-free survival rate of 94%,
ompared with 19% for the poor-risk group (P 
0006).
Although the Coleman system [49] is the most
idely accepted prognostic model, it has not been
idely tested prospectively, perhaps because of the
arity of the disease and the various treatment regi-
ens applied.
Slater et al. [50] treated 51 patients with LBL with
successive ALL protocols. An 80% CR rate was
chieved, which was nearly identical to that achieved
n 111 concurrently treated adult ALL patients. Seven
atients (14%) died while receiving therapy, 4 of
hom died from infectious causes. Slater et al. focused
n prognostic factors common to acute leukemia that
ight be relevant for the type of chemotherapy used
n the studied patients. Poor-prognostic factors in
heir report included age 30 years, white blood cell
ounts 50 000/mL, failure to achieve CR, and
ate CR.
In the German Multicenter Trials for Adult
cute Lymphoblastic Leukemia study (GMALL) on
-LBL, no signiﬁcant difference could be detected
etween low- and high-risk patients according to the
oleman model [3]. Furthermore, the relapse-free
urvival in high-risk patients (66%) was substantially
igher compared with the results (19%) in the original
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7ublication of the model [51]. When the International
rognostic Index for NHL [52] was applied to adult
BL patients, a decreasing survival was observed for
n increasing number of risk factors [53]. However, in
he German multicenter ALL series, the only signiﬁ-
ant prognostic factor for survival was increased LDH
2 times normal) in T-LBL patients [29]. No single
isk factor for relapse risk could be identiﬁed. How-
ver, patients with late achievement of CR (8 weeks)
fter ALL-type induction (GMALL 04/89 or 05/93)
ho required salvage treatment or who had increased
DH (2 times normal) had an inferior prognosis in
he context of this treatment regimen [51]. Similarly,
o prognostic factors were identiﬁed in the largest
eries in childhood T-LBL [54]. Neither age, nor
tage, nor LDH, nor immunophenotype seemed to
ffect DFS, in contrast to earlier pediatric studies in
hich disseminated disease, BM involvement, or age
14 years was associated with an inferior outcome
55]. The decreased relevance of the individual prog-
ostic factors may therefore be a consequence of more
ffective chemotherapy in adult, as well as childhood,
BL. The described prognostic factors should be seen
n the context of the treatment regimen used.
Because no convincing prognostic model is avail-
ble in LBL, new prognostic factors are required to
eﬁne indications for SCT in CR 1. For example,
able 2. Summary of Reported Prognostic Features for High-Risk Dise
Prognostic Features for Poor-Risk Disease
ailure to achieve CR after induction
DH level more than 1.5 times normal
dvanced stage III or IV disease
B” symptoms
ge >30 y
resent of >2 IPI risk factors
NS involvement at diagnosis
50 mitotic figures per high-power field in LN biopsy
one marrow involvement
nemia (Hbg <10 g/dL)
irculating lymphoblasts
BC >50  109/L
ctive CNS disease at autologous SCT
dvanced disease status (CR >2) at SCT
reatment with conventional NHL therapy vs. intensified regime
or ALL protocols (SCT)**
onventional chemotherapy vs. autologous SCT for consolidation
llogeneic SCT vs. autologous SCT (higher TRM in first 6 mo)
PI indicates International Prognostic Index; LN, lymph node; Hg
Failure to achieve CR or late CR (8 wk) after ALL-type inducti
LDH more than 2 times normal level.
LDH  1000 IU/mL.
LDH 500 IU/L.
Did not reach signiﬁcance in this study but showed a trend for po
Age 40 y.
BM involvement at SCT.
*Sweetenham et al. [53] reported inferior but not statistically d
Stanford/NCOG (an intensiﬁed NHL regimen).icroarray analysis of gene-expression proﬁles, as re- d
42ently published for T-cell ALL [56], may help to
dentify new prognostic markers in T-LBL. In child-
ood T-cell ALL, the decrease of blood blasts within
he ﬁrst days of therapy reported to be one of the most
mportant predictor of treatment outcome [57], but in
-LBL patients, a quantiﬁable parameter of response
o treatment is lacking. Monitoring of MRD is highly
redictive of treatment outcome in childhood ALL
58]. Whether this approach is also applicable and
redictive in T-LBL patients remains to be deter-
ined.
Rational assessment of individual treatment re-
ponse and relapse risk may be based on evaluation of
RD from BM or peripheral blood. This may lead to
ndividualization of therapy in LBL patients, includ-
ng SCT in ﬁrst remission. Methods are being estab-
ished for MRD evaluation from BM or even periph-
ral blood. It has already been demonstrated that most
-LBL patients show individual TCR rearrange-
ents, as in T-ALL. Thus, in the future, indications
or SCT may be based on the evaluation of MRD.
VOLUTION OF THERAPEUTIC APPROACHES
Understanding of lymphocyte biology and lym-
homagenesis has increased dramatically in the past 2
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Bace. Pediatric LBL was treated with radiotherapy
lone before 1970, and the 5-year survival rate was
nly 10%, with frequent leukemic transformations in
he later course of the disease: adult survivors beyond
years were rare. Initial success with conventional
HL chemotherapy protocols (CHOP [cyclophos-
hamide, hydroxydaunomycin {Doxorubicine}, Onco-
in {vincristine}, and prednisone] and the similar
OMP [cyclophosphamide, Oncovin {vincristine},
ethotrexate, and prednisone], BACOP [bleomycin,
driamycin {doxorubicin}, cyclophosphamide, Onco-
in {vincristine}, and prednisone], and mBACOD
methotrexate, bleomycin, Adriamycin {doxorubicin},
yclophosphamide, Oncovin {vincristine}, and dexa-
ethasone] protocols) was also limited to a CR rate of
3% to 71% and a DFS rate of 23% to 53% [59-63].
Response was improved (CR rates of 79%-100%
nd DFS rates of 23%-56%) with the use of modiﬁed
HL chemotherapies such as the Stanford/Northern
alifornia Oncology Group–like protocol, which
ncorporated asparaginase, CNS prophylaxis, and
aintenance chemotherapy [60,64,65]. As part of a
tanford/Northern California Oncology Group coop-
rative trial, Coleman et al. [49,66] reported their
bservations in 44 adult patients treated according to
4-phase protocol consisting of (1) induction with
yclophosphamide, doxorubicin, vincristine, pred-
isone, and methotrexate; (2) CNS prophylaxis; (3)
onsolidation with 4 additional cycles of the drugs
sed in induction; and (4) maintenance therapy with
ral methotrexate and 6-mercaptopurine for a total of
2 months of treatment. The overall response rate was
00% (95% CR), with an actuarial 3-year DFS of 58%
f the composite patient group [49].
Response rates were not improved with more in-
ensive high-grade NHL chemotherapies such as the
SA2-L2 and LNH-84 protocols designed for child-
ood NHL. CR rates were reported to be 57% to
3%, with a DFS of 35% to 44% [53,59,67]. How-
ver, the addition of SCT to LSA2-L2 chemotherapy
y Santini et al. [68] resulted in an improvement of
R to 84% with a DFS of 75%. These studies indi-
ated that intensiﬁed and prolonged chemotherapy
nd CNS prophylaxis are important strategies to im-
rove survival in LBL patients.
Picozzi and Coleman [69] suggested that an im-
ortant aspect of choosing initial therapy for newly
iagnosed cases of LBL is the degree of cytopenia at
resentation. Patients with signiﬁcant peripheral cy-
openia may well beneﬁt from ALL-type intensive
nduction chemotherapy to restore peripheral counts
n the shortest possible time. Patients with normal
eripheral blood counts at the outset of therapy usu-
lly achieve rapid clinical remission with less intensive
egimens that avoid signiﬁcant periods of marrow hy-
oplasia and its attendant infectious and hemorrhagic
isks [69]. s
B&MTWith the addition of an anthracycline, usually
aunorubicin or doxorubicin, to the backbone ALL
herapy of vincristine, prednisone, and, often, l-aspar-
ginase, CR rates of 72% to 92% have been achieved
n adults [70]. Given the high CR rate in ALL patients
bserved with these 4-drug induction regimens, it has
een difﬁcult to consistently demonstrate improve-
ent in overall CR rates with the addition of other
rugs, including cyclophosphamide or cytarabine, ex-
ept in T-lineage ALL, where they seem to improve
R, DFS, and overall survival rates [70]. Consistent
ith these ﬁndings, improvements in long-term out-
ome were achieved with ALL-type regimens for T-
BL, and in multiple series, CR rates of 55% to 100%
nd DFS rates of 45% to 65% have been reported
50,51,59,60,71-74]. The strongest evidence for the
igh efﬁcacy of ALL-type chemotherapy in T-LBL
ame from a recent report on 105 children with T-
BL [54]. This study showed that with intensive
LL-type chemotherapy, including moderate cumu-
ative doses of anthracyclines (240 mg/m2) and cyclo-
hosphamide (3 g/m2) and moderate-dose prophylac-
ic cranial irradiation (12 Gy after consolidation), but
o local radiotherapy, an event-free survival rate of
0% can be achieved in childhood T-LBL [54].
Thomas et al. [24] recently reported the outcome
f 33 adult LBL patients treated at M.D. Anderson
ancer Center (MDACC) with intensive chemother-
py by using the hyper-CVAD regimen (fractionated
yclophosphamide, vincristine, Adriamycin [doxoru-
icin], and dexamethasone) or the modiﬁed hyper-
VAD regimen used for ALL. Modiﬁcations included
he addition of a postinduction high-dose anthracy-
line and cytarabine course consisting of liposomal
aunorubicin 150 mg/m2 intravenously over 12 hours
n days 1 and 2 with cytarabine 1.5 g/m2 by contin-
ous infusion over 24 hours daily on days 1 and 2 (i.e.,
instead of 8 induction-consolidation courses were
iven). Prednisone (200 mg) was given orally daily for
days, and the maintenance therapy with mercapto-
urine, methotrexate, and monthly vincristine, and
rednisone (POMP) was extended to 3 years: early
nd late intensiﬁcations interrupted POMP. At diag-
osis, 80% of patients had a T-cell immunopheno-
ype, 70% had stage III or IV disease, 70% had me-
iastinal involvement, and 9% had CNS disease.
The results of the unmodiﬁed hyper-CVAD reg-
men in LBL were more encouraging. Overall, 91% of
atients achieved CR, and the estimated 3-year overall
urvival rate with standard hyper-CVAD was 83%,
ith a progression-free survival rate of 77%. Modiﬁ-
ation of the hyper-CVAD regimen with anthracy-
line intensiﬁcation did not improve outcome, be-
ause the best response for 3 patients treated with the
odiﬁed hyper-CVAD was a partial response. Thisuggests that early consolidation with high-dose
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7ethotrexate and cytarabine may be beneﬁcial for
ong-term progression-free survival.
The estimated 5-year durable remission and sur-
ival rates for previously untreated patients were 65%
nd 51%, respectively, for those treated in a recent
erman trial with the Berlin-Frankfurt-Munster
BFM) regimens [50] and were 62% and 67%, respec-
ively, for the T-cell subset reported in the MDACC
tudy [24].
Despite the signiﬁcant advances achieved in LBL
herapy, several issues are unsettled and remain topics
f active research: the optimization of induction ther-
py, the duration of maintenance therapy, the value of
NS prophylactic irradiation, and the effect of local
herapy modalities, especially mediastinal radiother-
py.
ANAGEMENT OF CNS AND MEDIASTINAL DISEASE
CNS involvement may be present in up to 20% of
dult T-LBL patients at presentation, and the CNS is
frequent site of relapse in the absence of CNS
rophylaxis [24]. Because of the strong correlation of
M involvement with CNS and/or testicular disease, a
ytologic evaluation of the spinal ﬂuid and adminis-
ration of intrathecal prophylactic CNS chemother-
py is mandatory for all T-LBL patients at the time of
iagnosis [29].
In the second series of Coleman et al. [49], earlier
dministration of intrathecal methotrexate and the
ddition of prophylactic cranial irradiation reduced
he incidence of CNS relapse from 29% to 3%, but
here was no signiﬁcant improvement in survival.
aken as a whole, CNS relapse rates range from 3%
o 42% in studies using intrathecal chemotherapy pro-
hylaxis alone, from 3% to 15% in studies using a
ombination of cranial radiation and intrathecal ther-
py, and from 42% to 100% in studies not incorpo-
ating any CNS-directed therapy (usually with NHL
rograms) [29]. The Pediatric Oncology Group study
75] found that the CNS relapse rate was similar
hether prophylaxis was intrathecal therapy alone or
as cranial radiation and intrathecal therapy. Many
rograms have eliminated irradiation because of con-
erns about the long-term neurologic sequelae [29].
espite prophylactic intrathecal prophylaxis with or
ithout radiotherapy, leptomeningeal relapses still oc-
ur in some patients, thus suggesting that the intensity
f systemic chemotherapy (e.g., high-dose methotrex-
te) may have a role in the reduction of CNS recur-
ence [76,77].
A recent German multicenter study [51] involving
large cohort of 45 adult T-LBL patients showed that
high CR rate and a favorable outcome could be
chieved with an ALL-type regimen. In this study, an
-drug standard induction was administered over 8 i
44eeks that included prophylactic cranial (24 Gy) and
ediastinal (24 Gy) irradiation followed by consoli-
ation and reinduction therapy. At diagnosis, 41
91%) of the 45 patients had a mediastinal tumor, and
8 (40%) had pleural/pericardial effusions; 33 (73%)
atients had stage III/IV disease. No CNS disease was
bserved in this study. Overall, 42 patients (93%)
chieved a CR, 2 patients (4%) achieved a partial
emission, and 1 patient (2%) died during induction as
result of tumor lysis syndrome. In patients with stage
to III disease (n  18), the CR rate was 100%,
ompared with 89% in stage IV disease (n  27). The
otal treatment duration was signiﬁcantly shorter (me-
ian, 8 months) compared with the conventional ALL
reatment of 2.5 to 3 years. Fifteen patients (36%)
elapsed within 12 months. Most relapses (47%) oc-
urred in the mediastinum (n  7) despite mediastinal
rradiation with 24 Gy in 6 of 7 patients. However,
ediastinal radiation therapy (24 Gy) comprised only
he anatomic mediastinum, not the original extent of
he mediastinal tumor, and mediastinal radiation ther-
py was given to 32 (84%) of 41 patients who pre-
ented with mediastinal disease [24,51]. Most patients
72%) had advanced stage III/IV disease, with in-
reased LDH values in 84% of the patients. The
verall characteristics of adult T-LBL observed in this
tudy [51] were similar to those in childhood T-LBL,
ncluding a male predominance, a high proportion of
ediastinal tumors, stage III/IV disease, and increased
DH. If the data from the above-mentioned German
dult T-LBL study are compared with data from the
FM group pediatric T-LBL study [54], there was a
igher incidence of BM involvement (31%) in the
dult cohort compared with the pediatric cohort
15%). In childhood NHL, all patients with medias-
inal involvement are allocated at least to stage III
isease according to Murphy’s system [78]. If this
ystem had been applied in this cohort of adults, the
ncidence of stage III/IV disease would have been
6%, exactly as in the childhood T-LBL study [54].
Mediastinal recurrence was the major obstacle.
urther improvement by intensiﬁcation of chemo-
herapy, increased doses of mediastinal irradiation (36
y), and extended indications for SCT was proposed
or solving this problem [51].
As noted previously, Thomas et al. [24] have re-
ently reported the outcome of adult LBL patients
reated with the intensive hyper-CVAD chemother-
py regimen used for ALL. CNS prophylaxis included
lternating intrathecal therapy with 12 mg of metho-
rexate (6 mg only if via Ommaya reservoir) on day 2
nd 100 mg of cytarabine on day 7 or 8 of each course
or a total of either 6 or 8 intrathecal treatments,
epending on the risk for CNS relapse (based on high
erum LDH level, high proliferative index, or both)
79]. Therapy for active CNS leukemia at presentation
ncluded an increase in the frequency of the alternat-
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Chemotherapy and Hematopoietic SCT for T-LBL
Bng intrathecal therapy during the induction course to
wice weekly until the cerebrospinal ﬂuid cytological
ndings were negative and the cell count was normal.
ntrathecal therapy was then administered weekly for
weeks and then according to the prophylactic sched-
le (2 intrathecal administrations per course) for the
emaining courses of intensive chemotherapy. No
rophylactic cranial irradiation was given. Therapeu-
ic radiation therapy (24-30 Gy in 10-12 fractions
irected to the base of the skull) was given if indicated
or CNS disease at presentation (e.g., with cranial
erve involvement). The incidence of isolated CNS
elapse was low (3%), thus suggesting that the com-
ination of high-dose systemic chemotherapy and ap-
ropriate intrathecal CNS chemotherapy [24] was ad-
quate CNS prophylaxis for alleviating the need for,
nd potential complications of, prophylactic cranial
rradiation for LBL. In the study of Hoelzer et al. [51],
one of the 45 patients had CNS disease at presenta-
ion. CNS relapse occurred in only 1 (2%) of the 45
atients treated with CNS prophylaxis, which con-
isted of 5 intrathecal chemotherapy applications and
ranial irradiation (24 Gy).
Although mediastinal radiotherapy is certainly ef-
ective local treatment [80], it carries several poten-
ially serious risks, including the development of car-
iac disease [81], radiation pneumonitis, secondary
alignancies [82,83] (e.g., breast cancer, bone sarco-
as in the radiation ﬁeld, myelodysplasia, and acute
yeloid leukemia), and other long-term sequelae,
specially in long-surviving children. Because of
hort- and long-term morbidity, as well as
ocoregional relapses [51], mediastinal radiotherapy
as been eliminated from most pediatric LBL proto-
ols [29,54]. Because of concerns about increased tox-
city with concomitant doxorubicin in 2 earlier pedi-
tric LBL studies, mediastinal irradiation was reserved
or respiratory compromise or vascular obstruction
ue to adenopathy [84,85]. Steroid therapy alone of-
en leads to rapid alleviation of signs and symptoms,
lthough mediastinal irradiation may sometimes be
eeded. Hence, if mediastinal disease results in respi-
atory distress or superior vena cava syndrome, an
ffort should be made to establish a tissue diagnosis
efore the initiation of therapy [29]. The incidence of
solated mediastinal relapse in the absence of prophy-
actic or consolidative radiotherapy ranges from 5% to
0% [54]. The routine administration of mediastinal
adiotherapy for all patients with mediastinal disease
emains controversial.
The management of residual mediastinal masses in
BL is also controversial. The options include local
adiotherapy, surgical resection of the residual mass,
r close observation if the patient is receiving main-
enance chemotherapy or if a SCT is being planned.
iable tumor can be detected at biopsy and autopsy
ccasionally, even in LBL patients who are apparently C
B&MTn CR. In one study of 60 patients who underwent
esection of a residual mediastinal mass after comple-
ion of therapy, 8% had pathologic evidence of resid-
al disease [29,85]. The specimens were necrotic in 3
atients, and 2 had residual tumor cells and underwent
ocal radiotherapy. Rappaport et al. [86] reported re-
idual neoplastic cells and ﬁbrosis in 3 out of 3 patients
ndergoing thymectomy during complete clinical re-
ission after chemotherapy.
The contribution of mediastinal radiotherapy to
FS in chemotherapy-treated patients may depend on
he efﬁcacy of the chemotherapy. The BFM group
eported 90% event-free survival in childhood T-LBL
54] with intensive ALL-type chemotherapy (includ-
ng moderate cumulative doses of anthracyclines [240
g/m2] and cyclophosphamide [3 g/m2]) and moder-
te-dose prophylactic cranial irradiation but no local
adiotherapy. Patients received an 8-drug induction
ver 9 weeks followed by an 8-week consolidation
ncluding methotrexate 5 g/m2  4. Patients with
tage I (n  2) and II (n  2) disease continued with
aintenance therapy (6-mercaptopurine daily and
ethotrexate weekly) for a total therapy duration of
4 months. Patients with stage III (n  82) and IV (n
19) disease received an 8-drug intensiﬁcation over 7
eeks and cranial radiotherapy (12 Gy for prophy-
axis) after consolidation, followed by maintenance.
esidual tumor after induction had to be resected.
atients received intensiﬁed chemotherapy if tumor
egression on day 33 of induction was 70% (n  2)
r if vital residual tumor was present after the com-
lete induction phase. In patients with a mediastinal
ass, a complete normalization of chest radiograph
esults on day 33 was considered a complete tumor
esponse.
In the case of residual mediastinal widening on
hest radiograph, a computed tomographic or mag-
etic resonance imaging study was performed. The
umor volume was calculated as height (cm)  width
cm)  depth (cm)  0.523. The percentage of tumor
egression was calculated as the initial tumor volume
inus the tumor volume on day 33 divided by the
nitial volume times 100. If there was 70% tumor
egression on day 33 and/or 5% BM blasts and/or
ersistent blasts in the cerebrospinal ﬂuid, then treat-
ent was intensiﬁed according to the high-risk arm of
he ALL-BFM 90 trial [87]. This childhood experi-
nce with the BFM regimen [54] (without consolida-
ive mediastinal radiation therapy) using intensive
igh-dose methotrexate (5 g/m2) resulted in a signif-
cantly lower rate of mediastinal relapse (7%), but this
ntensive high-dose methotrexate probably cannot be
elivered to adults without signiﬁcant toxicity [24,54].
n keeping with an earlier report [88], higher-dose
onsolidative mediastinal radiation therapy (30-39
y) given after a dose-intensive phase of hyper-
VAD in adult T-LBL patients seemed to reduce the
745
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7ncidence of locoregional relapse in the recent
DACC study [24]. Only 2 (12%) of 17 patients
reated with consolidative irradiation relapsed in the
ediastinum (and at other sites). Early progression in
he mediastinum occurred before consolidative irradi-
tion in 3 (13%) of the 23 patients for whom radiation
herapy was planned after 8 cycles of dose-intensive
herapy according to the protocol [24]. The authors of
hese studies suggest a possible role of appropriate
ose-consolidative mediastinal irradiation in adults
24,88]. However, because some patients experience
arly progression in the mediastinum, consolidative
rradiation (30-36 Gy) involving the entire extent of
he original mediastinal tumor may be tried earlier in
he course of the dose-intensive phase, especially for
low responders, in a randomized prospective clinical
rial involving adult T-LBL patients with mediastinal
isease. Further areas to be explored include concur-
ent administration of ALL-type chemotherapy and
lemtuzumab (a monoclonal antibody to CD52 with
igh expression in T-cell malignancies) with nelara-
ine (a nucleoside analogue with activity in previously
reated T-cell acute ALL, LBL, and other leukemias)
or slow responders or those with other high-risk
eatures [24,89].
In summary, the reported therapeutic approaches
o adult LBL include conventional protocols for
HL, intensive combination chemotherapy protocols
esigned for high-grade NHL, and protocols for the
reatment of ALL, with or without prophylactic cra-
ial irradiation (as in most ALL protocols) and with or
ithout prophylactic or therapeutic mediastinal irra-
iation. Furthermore, SCT, particularly autologous
CT, was included at different thresholds for the
eﬁnition of poor-risk disease in treatment strategies.
hese different treatment approaches in conjunction
ith differences in patient characteristics, particularly
edian age and the proportion of patients with stage
II/IV disease or advanced-disease status, may explain
he considerable variations in reported outcomes.
Despite the rarity of the disease and the large
umber of approaches applied in treatment of adult
BL, a few general statements can be made: First,
ore intensive ALL-type chemotherapy programs
eem superior to NHL-type regimens. Second, shorter-
erm chemotherapy without a maintenance phase seems
o increase the risk of relapse in LBL [11]. Third, an
ntensive intrathecal chemotherapy prophylaxis program
s required to reduce the incidence of CNS relapse. The
ole of cranial irradiation as an addition to prophylaxis is
nclear because several studies have reported low CNS
elapse rates with early intrathecal therapy alone, but
sually only with high-intensity systemic therapy that
ncludes a maintenance phase [71,77]. Fourth, incorpo-
ating adequate doses of consolidative mediastinal irra-
iation (involving the entire extent of the original tumor)
long with more intensive ALL-type chemotherapy reg- I
46mens may decrease mediastinal relapse [24]. Fifth, at-
empts to improve long-term outcome have resulted in
hemotherapy programs that incorporate consolidation
ith either autologous SCT or allogeneic bone marrow
ransplantation (BMT), thus clouding the true efﬁcacy of
ntensive chemotherapy alone [29].
OLE OF SCT IN T-LBL
Taken as a whole, intensive chemotherapy regi-
ens with or without irradiation in adult LBL have
mproved CR rates compared with previous lym-
homa regimens. Further attempts to improve long-
erm outcome have resulted in chemotherapy pro-
rams that integrate consolidation with either
utologous intensiﬁcation or allogeneic SCT. The
igh CR rate and high subsequent relapse rate provide
he rationale for the use of high-dose therapy and
CT to consolidate ﬁrst remission in LBL patients.
oth autologous and allogeneic SCT have been used
s consolidation therapy in high-risk LBL patients.
vailable data (in a satisfactory number of cases) sug-
est that intensive consolidation therapy followed by
utologous or allogeneic SCT may improve the long-
erm prognosis of this disease, but which patients may
eneﬁt from SCT remains unclear. Table 3 provides a
omprehensive summary of all recent trials and an
pdated composite report from previous key publica-
ions on SCT in LBL [3,29,90]. The use of autologous
CT in adults with LBL in ﬁrst remission produced a
rend for improved relapse-free survival but did not
mprove overall survival signiﬁcantly compared with
onventional-dose therapy in a small randomized trial
f the European Group for Blood and Marrow Trans-
lantation and the United Kingdom Lymphoma
roup [53]. However, studies from single centers and
egistries have resulted in 31% to 77% long-term
FS by using autologous SCT [53,59,60,72,91-97]
nd in 39% to 91% DFS in patients receiving alloge-
eic BMT in ﬁrst remission [60,53,92]. In patients
ith a more advanced disease status (CR 1), DFS
ith autologous SCT has been reported as 36% to
0% [59,93,97,98], and it has been reported as 14% to
6% in patients receiving allogeneic BMT [59,98,99].
owever, these data must be interpreted cautiously in
iew of the potential selection bias inherent in single-
nstitution and registry-based studies. Several of these
tudies restricted the use of high-dose therapy to pa-
ients thought to have poor-risk disease, although the
eﬁnition of “poor risk” has been inconsistent.
More recently, Levine et al. [98] published, on
ehalf of the Lymphoma Study Writing Committee,
he outcomes of 204 patients who underwent autolo-
ous (n  128) or HLA-identical sibling (n  76)
CT from 1989 to 1998 and were reported to the
nternational Bone Marrow Transplant Registry
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Chemotherapy and Hematopoietic SCT for T-LBL
BIBMTR) or Autologous Blood and Marrow Trans-
lant Registry (ABMTR). This is the largest series of
BL patients ever reported. Of 204 patients, 183 were
dult patients as deﬁned by age 16 years (Fasto
oberiza and Mary Horowitz, personal communica-
ion, 2003). Among adults, 118 (64.5%) patients re-
eived allogeneic SCT, and 65 (35.5%) received au-
ologous SCT. The median age of autologous patients
as 31 years (range, 2-67 years) and was 27 years
range, 5-53 years) for those who received HLA-iden-
ical sibling SCTs. Fifty-two IBMTR teams from 24
ountries and 64 ABMTR teams from 12 countries
eported analyzed data. A total of 76 (46%) of 165
egistered HLA-identical sibling transplantations and
28 (41%) of 312 registered autologous transplanta-
ions had comprehensive data available for analysis
nd were included in the study.
Autologous transplant recipients were older,
able 3. Summary of Reports on Stem Cell Transplantation in LBL*
Study
llogeneic SCT in CR 1
Milpied et al. [92]
Bouabdallah et al. [60]
Sweetenham et al. [53]
Levine et al. [98]
Total number of patients and weighted mean (range)
llogeneic SCT in CR >1 or persistent disease
Morel et al. [59]
van Besien et al. [99]
Levine et al. [98]
Total number of patients and weighted mean (range)
uto SCT in CR 1
Milpied et al. [92]
Baro et al. [93]
Morel et al. [59]
Bouabdallah et al. [60]
Verdonck et al. [94]
Santini et al. [95]
Sweetenham et al. [91]
Jost et al. [96]
Zinzani et al. [72]
Conde et al. [97]
Sweetenham et al. [53]
Levine et al. [98]
Total number of patients and weighted mean (range)
uto SCT in CR >1 or persistent disease
Baro et al. [93]
Morel et al. [59]
Conde et al. [97]
Levine et al. [98]
Total number of patients and weighted mean (range)
Includes data from Hoelzer et al,3 with permission.
For allogeneic SCT and autologous SCT together; no difference
Percentage, not probability.
DFS for all allogeneic SCT patients; relative risk of treatment fail
with CR1 SCT.
DFS at 3 years in CR2 (personal communication with Fausto Lob
Overall survival.
Including Burkitt lymphoma.
*DFS for all autologous SCT patients; RR of treatment failure inore likely to receive peripheral blood stem cells, a
B&MTore likely to receive transplants before 1994, and
ess likely to receive a total body irradiation–con-
aining conditioning regimen than allogeneic trans-
lant recipients. Allogeneic SCT recipients had
igher treatment-related mortality (TRM) at 6
onths (18% versus 3%; P  .002), and this disad-
antage persisted at 1 and 5 years. Graft-versus-host
isease (GVHD) was reported as the cause of death
n only 2 (7%) of the allogeneic transplant recipi-
nts. Infection, pneumonitis, and organ failure ac-
ounted for most TRM for both autologous and
llogeneic transplant recipients. Multivariate analy-
is revealed that donor source was the only signiﬁ-
ant predictor of TRM. Patients who received an
llogeneic transplant were 6.12 (95% conﬁdence
nterval, 2.25-16.56) times more likely to die of
reatment-related causes than autologous transplant
ecipients. The ﬁndings remained the same when
Year No. Patients DFS (%)
1989 12 68†
1998 11 91‡
2001 7 59
2003 24 39§
54 64 (39–91)
1992 7 14‡
1996 25 17
2003 52 46
84 26 (14–46)
1989 13 68†
1992 14 77
1992 5 60‡
1998 16 62‡
1992 9 67‡
1991 21 66
1994 105 63¶
1995 17 31#
1996 10 70†
1999 58 76
2001 31 55
2003 47 44**
241 62 (31–77)
1992 8 50
1992 7 43‡
1999 11 36
2003 81 44
107 43 (36–50)
served.
R 2 was 1.82 (95% conﬁdence interval, 1.03–3.22) as compared
nd Mary Horowitz).
2 was 1.82 (1.03–3.22) as compared with CR1 SCT.was ob
ure in C
eriza analyses were performed separately for patients in
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7rst CR and for patients with advanced-stage dis-
ase. Early relapse rates after allogeneic SCT and
utologous SCT were similar, but signiﬁcantly
ower relapse rates were observed in allogeneic SCT
ecipients at 1 and 5 years (32% versus 46% [P 
05] and 34% versus 56% [P  .004], respectively).
he 5-year cumulative incidences of relapse were
4% (95% conﬁdence interval, 23%-45%) after al-
ogeneic SCT and 56% (95% conﬁdence interval,
5%-65%) after autologous SCT (P  .004). There
as no statistically signiﬁcant effect of acute or
hronic GVHD on the risk of relapse for allogeneic
ransplant recipients, but low statistical power could
iss a small effect.
Multivariate analysis revealed that donor source,
ymphomatous involvement of the BM at transplan-
ation, and disease status at transplantation were
ndependent predictors of persistent or recurrent
ymphoma after SCT. No differences were noted in
ymphoma-free survival rates between allogeneic
CT and autologous SCT (5-year rates, 36% versus
9%; P  .82). Autologous SCT recipients had
igher overall survival at 6 months (75% versus
9%; P  .01), but survival did not signiﬁcantly
iffer between the 2 groups at 1 and 5 years (60%
ersus 49% [P  .09] and 44% versus 39% [P 
47], respectively). Multivariate analyses to account
or confounding factors conﬁrmed these results. In-
ependently of SCT type, BM involvement at the
ime of SCT and disease status more advanced than
rst CR were associated with inferior outcomes.
he DFS of patients who underwent autologous
ransplantation in CR 2 was 71%, 51%, and 44% at
months, 1 year, and 3 years, respectively. The
FS of patients who underwent allogeneic SCT in
R 2 was 62%, 55%, and 46% at 6 months, 1 year,
nd 3 years, respectively (Fausto Loberiza and Mary
orowitz, personal communication).
Although the report by Levine et al. [98] has
igniﬁcantly added to our understanding of LBL,
here are a few points to make. The 2 groups did not
iffer signiﬁcantly in other characteristics related to
he patient, disease, and treatment, but LDH at diag-
osis was 1.5 times the upper limit of normal in 157
atients (77%), and at the time of SCT, 166 (81%)
atients had no CNS involvement and 143 (70%) had
o BM involvement. It seems that most patients
acked these high-risk factors. Disease stage and im-
unophenotype were not analyzed, possibly because
f a lack of data. Only 102 (50%) patients were re-
orted to have received doxorubicin-containing initial
hemotherapy regimens, 24 (12%) had other chemo-
herapies without doxorubicin, and therapy was un-
peciﬁed in others.
In a retrospective analysis of our single-institution
ata for 28 LBL patients who received SCTs (unpub-
ished data), 15 received autologous peripheral blood T
48CTs, and 13 received allogenic sibling donor SCTs.
hese included 10 patients with B-LBL, 1 of un-
nown type, and 17 patients with T-LBL. DFS ac-
ording to immunophenotype for T-LBL at 3 years
as 41%, and for B-LBL it was 70%. DFS for the
ecipients of allogeneic SCTs and autologous SCTs at
years was 69% and 33%, respectively.
Different strategies toward further improvement
n frontline therapy for adult T-LBL should include
ntensiﬁcation of chemotherapy, prolonged mainte-
ance therapy (1-2 years according to the stage), in-
reased control of bulky or residual mediastinal dis-
ase (eg, by irradiation [36 Gy] or resection of the
esidual mass), and extended indications for SCT
100-103]. It is evident that all efforts for improve-
ent of treatment strategies have to be made in front-
ine therapy, because the outcome of patients with
elapsed T-LBL is poor. Taking all studies together,
he results of autologous SCT in LBL are inferior
eyond ﬁrst CR, with a 47% DFS rate for patients
ith LBL in second CR [3] and 15% for those with
esistant disease [91]. Late relapses (at 1 year) seen
ith autologous SCT may be decreased by the appli-
ation of allogeneic SCT [98].
Salvage treatment should therefore aim to refer
atients to an allogeneic SCT as soon as possible. In
atients without a compatible donor, autologous
CT in second remission is an option, and collec-
ion of peripheral stem cells after frontline treat-
ent has been performed in some series [51]. Ob-
iously, autologous stem cells are most useful for
atients who have no marrow involvement at pre-
entation or who have shown marrow clearance by
ethods used in MRD detection, including immu-
ophenotyping and TCR gene-rearrangement stud-
es. Recent data suggest that in vitro purging, pos-
tive selection, or in vivo purging may be beneﬁcial,
lthough randomized trials are the only way to
rove the value of these approaches [104]. In the
argest report (of 204 LBL patients [98]), infection,
neumonitis, and organ failure accounted for most
RM for both autologous and allogeneic transplant
ecipients. This aspect can be improved by better
ools available, including the use of granulocyte
olony-stimulating factor and newer antifungal
gents. In the same article [98], multivariate analysis
evealed that donor source was the only signiﬁcant
redictor of TRM both in CR 1 and in advanced-
tage disease [98]. Application of a reduced-inten-
ity conditioning strategy may help in overcoming
his disadvantage of allogeneic SCT.
Furthermore, new cytostatic drugs (such as
ladribine and 506U78 [105]) that have speciﬁc activ-
ty on T cells or immunotherapy with T cell–speciﬁc
ntibodies (such as anti-CD3 and anti-CD52) deserve
valuation in patients with relapsed and refractory
-LBL to improve the chance of a second remission
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Chemotherapy and Hematopoietic SCT for T-LBL
B51]. The roles of new chemotherapeutic agents and
ore aggressive approaches, including the use of re-
ently described prophylactic donor lymphocyte infu-
ions (DLIs) for more aggressive disease [114], need to
e explored in future clinical trials involving LBL
atients.
RAFT-VERSUS-LYMPHOMA IN T-LBL COMPARED
ITH OTHER LYMPHOMAS
An immune-mediated antitumor effect against
alignant lymphomas after allogeneic SCT, referred
o as the graft-versus-lymphoma (GVL) effect, was
uggested by Jones et al. [106] from Johns Hopkins
edical Institutions in 1991. Interest in exploring the
VL effect in lymphoma patients has grown recently,
lthough either studies have included few LBL pa-
ients or the number of LBL patients has not been
eported separately. The strongest argument that a
linically relevant GVL effect exists was the demon-
tration of NHL regression after withdrawal of im-
une suppression or by post-SCT DLI in some series
107-109]. Ratanatharathorn et al. [110] conducted a
rospective study comparing allogeneic and autolo-
ous BMT after myeloablative conditioning in 66
onsecutive patients with recurrent NHL. The prob-
bility of disease progression was signiﬁcantly higher
n the autologous group (P  .001), thus suggesting a
VL effect [110].
Until recently, it has been a general notion that
VL probably exists only in low-grade lymphomas,
ut, as discussed below, there is a need to further
nderstand and accentuate alloreactivity toward
-LBL. Combining review of some earlier studies and
ost recent studies focused on the exploitation of a
VL effect. It is easy to ﬁnd evidence of at least a
ow-level GVL, even in most aggressive diseases, in-
luding T-LBL/T-ALL.
In a case-controlled analysis of the European Bone
arrow Transplant Group Registry data, allogeneic
MT was associated with a lower relapse rate than
utologous BMT (24% versus 48%; P  .035) in the
BL subgroup. A signiﬁcantly lower relapse/progres-
ion rate was also observed in patients with chronic
VHD compared with patients without chronic
VHD (0% versus 35%; P  .02). Fourteen of 18
atients who had chronic GVHD also had LBL. This
tudy concluded that in LBL, a GVL effect might
ccount for the lower relapse rate for patients who
nderwent allogeneic BMT [111]. However, patients
ith LBL who underwent allogeneic BMT had a
igher TRM (24% for allogeneic BMT versus 10%
or autologous BMT; P  .06) [111].
Robinson et al. [107] reported the outcome of
educed-intensity allogeneic progenitor SCT for
88 patients with lymphoma from the Lymphoma m
B&MTorking Party of the European Group for Blood
nd Bone Marrow Transplantation. Of 188 patients,
2 had high-grade NHL (including diffuse large
-cell, centroblastic, immunoblastic, anaplastic
arge cell, pre–B-LBL, pre–T–LBL, peripheral T-
ell, and angioimmunoblastic lymphoma and 7 with
ransformed low-grade NHL). The median age of
he patients was 40 years, the median number of
rior treatment courses was 3, and 48% of patients
ad undergone a prior autologous transplantation.
ull donor chimerism was conﬁrmed in 71% of 100
atients assessed. Acute GVHD developed in 37%
f patients, and chronic GVHD, in 17%. A disease
esponse to DLI was seen in 10 of 14 patients. With
median follow-up of 283 days, the overall survival
ates at 1 and 2 years were 62% and 50%, respec-
ively. The 100-day and 1-year TRM rates were
2.8% and 25.5%, respectively, and were signiﬁ-
antly higher for older patients. The probabilities of
isease progression at 1 year for patients with che-
oresistant and chemosensitive disease were 75%
nd 25%, respectively (P  .001). Those with che-
oresistant disease included those with primary re-
ractory disease or refractory relapse before SCT.
he progression-free survival at 1 year of 46% was
igniﬁcantly better for those with chemosensitive
isease, Hodgkin disease, and low-grade NHL.
The databases of the IBMTR, the European
roup for Blood and Marrow Transplantation, and
he ABMTR were recently combined and analyzed by
ierman et al. [104]. The analysis compared the re-
apse rates of NHL patients who underwent synge-
eic, autologous (purged versus unpurged), or alloge-
eic (T cell–replete versus T cell–depleted)
ematopoietic SCT. A total of 4176 patients, includ-
ng 686 patients with high-grade histology and 89
yngeneic transplant recipients, were identiﬁed.
According to their interpretation of the data, the
uthors state that a clinically relevant GVL effect was
ot detectable in NHL patients who received an allo-
eneic SCT, and they suggest that greater emphasis
hould be placed on autologous stem-cell graft con-
amination, relative to its contribution to relapse.
owever, the data should be reviewed and interpreted
autiously, as pointed out by Bishop [112]. The cases
n the analysis presented by Bierman et al. [104] were
xtremely heterogeneous relative to histology and
ultiple other characteristics of NHL, including the
vailability of stem-cell source (allogeneic donor avail-
bility and BM involvement), disease status (induction
ailure versus remission versus relapse), and disease
ensitivity to chemotherapy. Regardless of histology,
he overwhelming majority (70%) of NHL patients
eferred for autologous SCT have chemotherapy-sen-
itive disease, as opposed to 40% of patients who
nderwent allogeneic SCT in this study [104]. Adjust-
ents were made to compensate for the lack of data
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7or chemotherapy sensitivity, but the numbers of com-
arable patients then became increasingly smaller, es-
ecially when additional variables, such as histology,
ere included [112]. It is possible that a GVL effect
as present among the patients who were analyzed in
he combined registries analysis, but a clinically ben-
ﬁcial effect relative to other disease characteristics,
uch as histology and chemotherapy sensitivity, could
ot be detected [112].
Chemotherapy sensitivity may be the most impor-
ant factor in SCT for LBL and other lymphomas. For
atients with chemotherapy-sensitive disease, a GVL
ffect, if it exists, may contribute little because patients
ay already be cured by the myeloablative condition-
ng. In extremely chemotherapy-refractory patients, it
ay not be sufﬁciently potent to be detectable because
he tumor growth rate exceeds the ability of the im-
une effect to eliminate the disease. In all multivari-
te analyses run on the combined registry data, che-
otherapy sensitivity was a signiﬁcant variable across
ll histological ﬁndings [104]. If one goes back to the
nalogy of acute leukemias and CML, it would have
een difﬁcult to identify a graft-versus-leukemia effect
f it had been performed in relapsed acute leukemias
nd advanced-phase CML [112,113]. Because the
ultivariate analysis in the LBL study by Levine et al.
98] revealed donor source as the only signiﬁcant pre-
ictor of TRM both in CR 1 and in advanced-stage
isease, application of a reduced-intensity condition-
ng strategy may help in overcoming this disadvantage
f allogeneic SCT [98].
Chemotherapy sensitivity remains an important
rognostic factor even in reduced-intensity allogeneic
CT for NHL. In a retrospective analysis from the
uropean Group for Blood and Marrow Transplan-
ation on the use of reduced-intensity allogeneic SCT
n malignant lymphomas, the 1-year progression-free
urvival for patients with chemotherapy-sensitive and
hemotherapy-resistant disease was 75% and 25%,
espectively (P  .001) [107]. It is interesting to note
hat there were no relapses among patients who re-
eived transplants from unrelated donors; this sug-
ests that greater histocompatibility differences may
ccentuate a beneﬁcial GVL effect. Another impor-
ant observation from this article was that the use of
LI in 14 patients with recurrent or persistent disease
esulted in responses in 10 patients, including 6 CRs.
here is a need to further understand and accentuate
lloreactivity toward T-LBL. These questions are all
xtremely relevant to hematopoietic SCT for LBL
nd other lymphomas, and it is hoped that these issues
ill be addressed in future clinical trials [112].
Application of a reduced-intensity conditioning
trategy may help in overcoming the disadvantage of
igh early TRM seen with allogeneic SCT [98]. How-
ver, this transplantation modality should be re-
tricted to LBL patients with a minimal-disease status. d
50etter methods for MRD detection need to be ex-
lored in LBL patients to optimize this strategy.
Future studies are required to deﬁne whether the
equential use of autografting for cytoreduction and
ncorporation of less toxic nonmyeloablative prepara-
ive regimens for high-risk LBL patients with minimal
isease may promote engraftment and generation of a
VL effect that will bring in much of the beneﬁt of
llogeneic SCT in eliminating residual lymphoma and
inimizing the TRM. The success of this strategy has
lready been shown in other NHL and Hodgkin dis-
ase patients [83].
In a more aggressive approach, Arnold et al. [114]
rom Germany have recently shown remarkably im-
roved survival (60% in CR 1 and 49% in CR1) and
ecreased relapse probability with the administration
f prophylactic DLI in adults with high-risk ALL,
ncluding mature T-ALL patients who did not de-
elop GVHD after allogeneic SCT. This study again
upports a GVL effect in mature T-ALL (which is
nalogous to stage IV T-LBL) at a level that requires
LI to become evident.
ONCLUSION
The collective experience in the management of
dult T-LBL suggests a good outcome of patients
ith no adverse prognostic factors treated with an
LL-like treatment strategy. Patients with adverse
rognostic features should be considered for more
ggressive therapy—speciﬁcally, high-dose chemo-
herapy and SCT. Although comparative data about
he relative efﬁcacy of allogeneic versus autologous
CT in T-LBL are limited, it seems that the out-
omes of these 2 transplant modalities are similar for
atients in CR 1, particularly if there is no BM in-
olvement. However, allogeneic SCT is likely to be a
ore appropriate option for patients who are beyond
R 1, who have more advanced disease, or who have
M involvement, because this transplantation modal-
ty may have the potential advantage of a GVL effect.
or the best outcome with allogeneic SCT, the pa-
ient should be in a MRD status, particularly if re-
uced-intensity allogeneic SCT is used. The roles of
onoclonal antibodies and more aggressive ap-
roaches, including the use of recently described pro-
hylactic DLIs for more aggressive disease, need to be
xplored in future clinical trials.
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